EUVIMEDEUVIMED entdecken
Open Access

Sex- and age-specific sensitivities of the endocannabinoid system in Alzheimer's disease revealed by PET imaging with [ 18 F]FMPEP- d 2 and [ 18 F]MAGL-2102

Anna Pees, Christopher Daniel Morrone, Junchao Tong, Jian Rong, Tuo Shao, Darcy Wear, Steven H Liang, Wai Haung Yu, Neil Vasdev

Theranostics · 2025

DOI: 10.7150/thno.106592 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, 2025. Verfasst von Anna Pees und 8 weiteren Autor:innen. Beteiligte Einrichtung: Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Ment…. Hauptthemen laut MEDLINE: Alzheimer Disease, Endocannabinoids. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The endocannabinoid system is a critical brain signaling pathway that is dysregulated in various brain disorders, including Alzheimer's disease (AD).Cannabinoid-targeted therapies and imaging approaches have gained increasing interest; however, the biological impact of the endocannabinoid system in disease needs further validation.We aimed to study changes in cannabinoid receptor 1 (CB1) and monoacylglycerol lipase (MAGL), components of endocannabinoid signaling and degradation, in a mouse model of AD by PET imaging.Methods: [ 18 F]FMPEP-d2 and [ 18 F]MAGL-2102 were produced on a commercial radiosynthesis module.PET-CT images with both tracers were acquired in a knock-in mouse model of AD bearing mutated human amyloid precursor protein (App NL-G-F ) at 3 ages, and compared to wild-type mice.Excised brains were used for in vitro autoradiography with [ 18 F]FMPEP-d2 and [ 18 F]MAGL-2102, immunofluorescence, and western blotting.Male wild-type and 5xFAD mice were chronically treated with MAGL inhibitor JZL184 and imaged with [ 18 F]MAGL-2102 two days after ending treatment.

Results

PET imaging showed sex-, age-and genotype-dependent changes in CB1 and MAGL availability.At 4-months (early-stage β-amyloid pathology), female App NL-G-F mice had lower CB1 availability, and MAGL availability was increased in male App NL-G-F , compared to wild-types.At 8-months, no genotype differences in CB1 were observed, yet MAGL availability was reduced in App NL-G-F frontal cortex, and male App NL-G-F mice exhibited higher MAGL than transgenic females brain-wide.At 12-months (late-stage β-amyloid pathology), significantly lower uptake of [ 18 F]FMPEP-d2 was observed in App NL-G-F compared to wild-type, with no changes in [ 18 F]MAGL-2102 binding.App NL-G-F plaque staging was confirmed by Thioflavin-S staining.Imaging findings were supplemented by autoradiography, immunofluorescence, and western blots.[ 18 F]MAGL-2102 availability was responsive to target engagement of the MAGL inhibitor JZL184 in wild-type and 5xFAD mice.

Conclusions

The present study showed dynamic age-, sex-and pathology-related changes in CB1 and MAGL availability from early-stage β-amyloid pathology, suggesting that the endocannabinoid system is a useful target for diagnostics and treatment of AD.Finally, these results highlight that endocannabinoid sex differences should be considered in diagnostics and drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseEndocannabinoidsAnimalsFemaleMiceMaleMice, TransgenicBrainDisease Models, AnimalPositron-Emission TomographyHumansMonoacylglycerol LipasesReceptor, Cannabinoid, CB1Fluorine RadioisotopesAmyloid beta-Protein PrecursorAge FactorsSex FactorsPositron Emission Tomography Computed Tomography

Stichwörter der Autor:innen

Alzheimer's diseasePETcannabinoid receptor 1endocannabinoid systemmonoacylglycerol lipase

Substanzen

EndocannabinoidsMonoacylglycerol LipasesReceptor, Cannabinoid, CB1Fluorine RadioisotopesAmyloid beta-Protein Precursor

Autor:innen und Institutionen

  • Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada, M5T 1R8.
  • Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia, United States.
  • Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States.
  • Jiangsu Key Laboratory of Infection and Immunity, Suzhou Medical College, Suzhou, China.
  • Department of Pharmacology & Toxicology, University of Toronto, Ontario, Canada.
  • Department of Psychiatry, University of Toronto, Ontario, Canada.

Förderung

  • NIDA NIH HHS
  • NIA NIH HHS

Zitieren

APA

Pees, A., Morrone, C. D., Tong, J., Rong, J., Shao, T., Wear, D., Liang, S. H., Yu, W. H., & Vasdev, N. (2025). Sex- and age-specific sensitivities of the endocannabinoid system in Alzheimer's disease revealed by PET imaging with [ 18 F]FMPEP- d 2 and [ 18 F]MAGL-2102. Theranostics. https://doi.org/10.7150/thno.106592

Vancouver

Pees A, Morrone CD, Tong J, Rong J, Shao T, Wear D, et al. Sex- and age-specific sensitivities of the endocannabinoid system in Alzheimer's disease revealed by PET imaging with [ 18 F]FMPEP- d 2 and [ 18 F]MAGL-2102. Theranostics. 2025. doi:10.7150/thno.106592

BibTeX
@article{Pees2025,
  author = {Pees, Anna and Morrone, Christopher Daniel and Tong, Junchao and Rong, Jian and Shao, Tuo and Wear, Darcy and Liang, Steven H and Yu, Wai Haung and Vasdev, Neil},
  title = {Sex- and age-specific sensitivities of the endocannabinoid system in Alzheimer's disease revealed by PET imaging with [ 18 F]FMPEP- d 2 and [ 18 F]MAGL-2102},
  journal = {Theranostics},
  year = {2025},
  doi = {10.7150/thno.106592}
}
Kostenlos starten →